SAO TOME AND PRINCIPE



I. Epidemiological profile

Population	2014	%
High transmission (>1 case per 1000 population)	186 000	100
Low transmission (0–1 cases per 1000 population)	0	0
Malaria free (0 cases)	0	0
Total	186 000	

Parasites and vectors

Major plasmodium species:	*P. falciparum* (100%), *P. vivax* (0%)
Major anopheles species:	*An. gambiae*
Programme phase:	Control

Reported confirmed cases:	1754	Estimated cases, 2013:	[12 000–25 000]
Reported confirmed cases at community level:	0		
Reported deaths:	0	Estimated deaths, 2013:	<100

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2005
	ITNs/LLINs distributed to all age groups	Yes	2008
IRS	IRS is recommended	Yes	2003
	DDT is authorized for IRS	No	–
Larval control	Use of larval control recommended	Yes	2004
IPT	IPT used to prevent malaria during pregnancy	Yes	2004
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2001
	Malaria diagnosis is free of charge in the public sector	Yes	2008
Treatment	ACT is free for all ages in public sector	Yes	2008
	Sale of oral artemisinin-based monotherapies	Is banned	2004
	Single dose of primaquine is used as gametocidal medicine for *P. falciparum*	Yes	2013
	Primaquine is used for radical treatment of *P. vivax*	Yes	2013
	G6PD test is a requirement before treatment with primaquine	No	–
	Directly observed treatment with primaquine is undertaken	Yes	2013
	System for monitoring of adverse reactions to antimalarials exists	Yes	2004
Surveillance	ACD for case investigation (reactive)	Yes	2008
	ACD of febrile cases at community level (pro-active)	Yes	2013
	Mass screening is undertaken	Yes	2014
	Uncomplicated *P. falciparum* cases routinely admitted	No	–
	Uncomplicated *P. vivax* cases routinely admitted	No	–

Antimalaria treatment policy	Medicine	Adopted
First-line treatment of unconfirmed malaria	AS+AQ	2004
First-line treatment of *P. falciparum*	AS+AQ	2004
Treatment failure of *P. falciparum*	AL	2004
Treatment of severe malaria	QN	2004
Treatment of *P. vivax*	–	–
Dosage of primaquine for radical treatment of *P. vivax*		–
Type of RDT used		*P. f* + all species (Combo).

Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
–	–	–	–	–	–	–	–

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)

Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2014–2015	-	-	No	-	*An. gambiae s.s.*

III. Financing

Sources of financing



Financing by intervention in 2014



IV. Coverage

ITN and IRS coverage



Cases tested and treated in public sector



Cases tracked



Test positivity



V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths



Impact: On track for >75% decrease in incidence 2000–2015